Across TCGA pan-cancer cohorts, ZNF92 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF92 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ZNF92 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF92 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, LUSC, and KIRP are the cancer types where ZNF92 Mutation most reproducibly stratifies survival.